INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,842 | +22.2% | 1,264 | +48.5% | 0.01% | -12.5% |
| Q2 2023 | $53,885 | +84.6% | 851 | +57.9% | 0.02% | +77.8% |
| Q1 2023 | $29,187 | +5.3% | 539 | +2.9% | 0.01% | 0.0% |
| Q4 2022 | $27,730 | +38.6% | 524 | +23.6% | 0.01% | -10.0% |
| Q3 2022 | $20,000 | -20.0% | 424 | -2.5% | 0.01% | -33.3% |
| Q2 2022 | $25,000 | -70.9% | 435 | -69.1% | 0.02% | -65.1% |
| Q1 2022 | $86,000 | – | 1,407 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |